MEDIUMClinicalTier 1
Maresin 1 Resolves Inflammation and Aids Bone Healing in Periapical Lesions
SourceJournal of Dental Research (JDR)Tier 1Peer-Reviewed Research
By E. Demir, I. İlgenli, Z. Guney, S. Mohammadi, K. Lauwens, N. Yakar, C. Alvarez Rivas, O. Unlu, A. Kantarci
Originally at journals.sagepub.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Maresin 1 (MaR1) shows promise as a targeted anti-inflammatory therapy that could accelerate bone healing in periapical lesions, potentially shortening treatment times and improving outcomes for endodontists and restorative dentists managing chronic apical periodontitis.
Key points
- Study published in Journal of Dental Research (Aug 2026) directly tested MaR1 in chronic apical periodontitis (CAP) models with measurable bone-healing endpoints.
- MaR1 is a specialized pro-resolving mediator (SPM) that actively resolves inflammation rather than suppressing it, differing from corticosteroids or NSAIDs.
- If translated to clinical use, MaR1 could be delivered via intracanal medicaments or local carriers, impacting both non-surgical retreatment and apical surgery protocols.
- Endodontists and specialists managing persistent lesions after conventional RCT may gain a biologically based adjunct to reduce residual inflammation and speed osseous repair.
Who should care
SpecialistAssociate
Read the original on Journal of Dental Research (JDR)
Full reporting and any paywall content live on journals.sagepub.com. We summarize and score; we do not republish.